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CHAPTER 1 Introduction 
Irinotecan was approved by the FDA as a second-line therapy for metastatic colon or rectal 
cancer in 1996. It is derived from the plant alkaloid camptothecin (CPT) and specifically inhibits 
eukaryotic DNA enzyme topoisomerase I. However, one of the leading side effects of irinotecan 
is severe diarrhea. After oral administration, irinotecan is metabolized into SN-38G in the liver, 
then SN-38G is excreted to the intestinal tract and deconjugated back to SN-38 by intestinal 
bacterial β-glucuronidase. The free SN-38 in the gut leads to the delayed diarrhea by damaging the 
intestinal mucosa. Therefore, selectively inhibiting the bacterial β-glucuronidase has become a 
promising strategy to alleviate irinotecan-induced delayed diarrhea. The purpose of this project is 
to explore more potent and higher selective inhibitors of bacterial β-glucuronidase from noni fruits, 
aiming to alleviate the irinotecan-induced delayed diarrhea with minimized side effects. 
1.1. Irinotecan and Delayed Diarrhea 
Camptothecin (CPT) was firstly discovered by Dr. Monroe E. Wall and Dr. Mansukh C. 
Wani in the early 1960s (1). It is from Camptotheca acuminata Decne (family Nyssaceae), a tree 
native to China (Figure 1). Earlier to the late 1950s, the Eastern Regional Research Laboratory 
(ERRL) of USDA screened approximate 1000 ethanolic plant extracts for antitumor activities. The 
Camptotheca extract was shown high antitumor activity by the CA-755 assay. Then, Dr. Wall and 
Dr. Wani conducted antitumor assay-guided isolation on the extracts of the tree’s wood and bark. 
The obtained monoterpene indole alkaloid (MIA), CPT (Figure 2), showed remarkable activity in 
the life prolongation of mice treated with L1210 leukemia cells, with doses between 0.5 and 4.0 






of solid tumors, such as water insoluble 9-nitro- and 9-amino-CPT, and water-soluble analogs of 
10-hydroxy-CPT that includes CPT-11 (Figure 2) and topotecan. 
 
Figure 1. The trees, flowers and fruits of Camptotheca acuminata 
 
By 1985, it was discovered that CPT and its analogues can specifically inhibit the 
eukaryotic DNA enzyme topoisomerase I, which produces transient single-stranded DNA breaks 
but doesn’t require ATP (2, 3). The levels of topoisomerase I are dramatically elevated in some 
tumor cells, and also relatively high in quiescent and proliferating cells (4, 5). During the early S-
phase of cell cycle, a cleavable complex that links topoisomerase and DNA is formed to unwind 
the DNA double helix prior to the replication fork. CPT and its analogues act to irreversibly arrest 
the replication fork by breaking the cleavable complex, which subsequently ceases DNA 
replication and results in cell death (6, 7). The findings of this unique anticancer mechanism greatly 
boosted the clinical trials of CPT and its analogues. Those compounds involved in a broad 






colorectal cancer and cervical cancer (7). Among them, CPT-11, also called irinotecan, was 
successfully developed as an anticancer drug. It was originally developed by Japanese 
pharmaceutical companies Yakult Honsha and Daiichi, and firstly approved in Japan in 1994, then 
in France in 1995. It was approved by the FDA of United States in 1996, as a second-line therapy 
for metastatic colon or rectal cancer (1, 8).  
      
Figure 2. The chemical structures of camptothecin (CPT, left) and irinotecan (CPT-11, right) 
 
Up to date, irinotecan has been widely used to treat colorectal, lung and pancreatic cancers 
(9). However, like other chemotherapeutic agents, such as fluorouracil and capecitabine of 
fluoropyrimidines, one of the leading side effects of irinotecan is diarrhea, which is also called 
chemotherapy-induced diarrhea (CID) (10). It has been reported that up to 88% of patients treated 












Table 1. Common Terminology Criteria for Adverse Events for Diarrhea 
Grade Diarrhea Criteria 
1 Increase of < 4 stools per day over baseline; mild increase in ostomy 
output compared with baseline 
2 Increase of 4-6 stools per day over baseline; moderate increase in ostomy 
output compared with baseline 
3 Increase of ≥7 stools per day over baseline; incontinence; hospitalization 
indicated; severe increase in ostomy output compared with baseline; 
limiting self-care activities of daily life 
4 Life-threatening consequences; urgent intervention indicated 
5 Death 
 
Irinotecan may induce acute and delayed diarrhea (13). The acute diarrhea occurs 
immediately after administration due to acute cholinergic properties. It is does-dependent and 
could be rapidly and effectively treated by atropine (14). The delayed diarrhea happens more than 
24 hours after drug administration. It is always a serious and dose-limiting adverse effect (14, 15). 
In the liver, irinotecan is metabolized by carboxylesterases (CE) to produce SN-38, which exerts 
100 to 1000-fold more potent cytotoxicity than irinotecan (16). Then, SN-38 is conjugated to the 
inactive and non-toxic SN-38-glucuronide (SN-38G) via uridine diphosphate-
glucuronosyltransferase 1A1 (UGT1A1). SN-38G is further excreted to the intestinal tract through 
the bile duct. In the gut, SN-38G is deconjugated back to SN-38 by bacterial β-glucuronidase 
(Figure 3). Even though the exact mechanisms are still in debate (13), this free SN-38 in the gut 
can damage the intestinal mucosa, which is responsible for the delayed diarrhea (17, 18).  
1.2. Bacterial β-Glucuronidases and Inhibitors 
The treatments of irinotecan-induced delayed diarrhea are still challenging. The National 






assessment and management of chemotherapy-induced diarrhea, which were published in 2004 
and updated in 2014 (19, 20). According to the guidelines, the delayed diarrhea could be managed 
through dietary modification and using of antidiarrheal medicines based on specific mechanisms, 
such as somatostatin analog octreotide, loperamide and deodorized tincture of opium. However, 
these therapies may either worsen existing gastrointestinal symptoms, or cause other adverse 
effects like uneven heartbeat, respiratory depression, neurotoxicity and seizures (21). Therefore, 
more effective therapies for the delayed diarrhea are still urgently needed, and emerging new 
methods have been investigated, including herbal extracts, phytochemicals and probiotics (12, 21).  
β-Glucuronidases are members of glycosyl hydrolases that involve in the breakdown of 
complex carbohydrates (22). Human β-glucuronidases exist in the lysosomes of most tissues and 
body fluids (23). In the gut, brush border β-glucuronidases are mainly secreted by the bacteria of 
Enterobacteriaceae family, including Salmonella, Klebsiella, Yersinia, Shigella, and especially 
Escherichia coli. Gut bacterial β-glucuronidases assist the microbiota in harnessing available 
glycosyl units as carbon sources, they are also the key mediators of intestinal toxicities associated 







Figure 3. The mechanism of irinotecan-induced delayed diarrhea involving the production of 
intestinal SN-38 
As discussed above, the bacterial β-glucuronidase is essential for the generation of 
intestinal SN-38. Alternative strategies targeting this enzyme have been paid increasing attention 
along with the clinical application of irinotecan. They are aiming to alleviate the delayed diarrhea 
by reducing the generation or inhibiting the activity of bacterial β-glucuronidase (Figure 3). Broad-
spectrum antibiotics have been used to reduce the production of bacterial β-glucuronidase by 
killing intestinal bacteria, such as penicillin and streptomycin (25, 26), neomycin (26), and the 
combination of cholestyramine and levofloxacin (27). However, these methods remove or 
modulate the gut bacteria, which may disorder the normal microbial metabolism of carbohydrate, 
vitamin and bile acids (28, 29), or increase the risks of pathogenic infection, such as Clostridium 
difficile and Escherichia coli (30-32). As a result, the using of antibiotics may deteriorate the poor 
health of patients who are suffering from the other side effects of chemotherapy (33). 
It has initiated another active strategy to develop selective inhibitors against the enzyme 






inhibition against β-glucuronidase from mouse liver (34, 35). In 2004, saccharic acid 1.4-lactone 
was proven in animal experiment to be able to reduce mucosal damage induced by irinotecan, 
however, exhibited a relatively low potency (36). The Kampo medicine (Hangeshashin-to) TJ-14 
was also investigated for irinotecan-induced diarrhea (37, 38). Its protective effects were 
tentatively attributed to the glucuronides, such as baicalin, wogonoside, luteolin-3′-glucuronide 
and glycyrrhizin, due to their potential inhibition against β-glucuronidase (39, 40). But the exact 
mechanisms of the Kampo extracts remain unclear. Since 2010, a group from the University of 
North Carolina has published a series of research papers in this area. For the first time, they 
reported inhibitors against β-glucuronidase from intestinal bacteria, instead of mammalian host. 
Those compounds selectively inhibited bacterial β-glucuronidase with IC50 in the range of 0.28-
4.8 µM (33, 41, 42). More importantly, they could reduce the irinotecan-induced gastrointestinal 
damage, while without killing intestinal commensal bacteria and not toxic to the host intestinal 
cells (11). Cheng et al. also reported pyrazolo[4,3-c] quinoline derivatives as specific inhibitors of 
bacterial β-glucuronidase, without impacting the antitumor efficacy of irinotecan in mice (43, 44). 
These inhibitors of bacterial β-glucuronidase have not achieved very potent and specific effects, 
however, they represent a very promising orientation to develop supplemental or therapeutic 
approaches to alleviate irinotecan-induced delayed diarrhea with minimized side effects. 
1.3. Specific Aims 
In a preliminary experiment, we screened about 50 extracts for their inhibitory activities 
against bacterial β-glucuronidase. Among them, an extract from noni fruits showed significant 
inhibition on the enzyme. The purpose of this study is to further investigate the chemical 






intestinal bacterial β-glucuronidase, aiming to alleviate the delayed diarrhea induced by irinotecan 
administration, while with minimized side effects on the gastrointestinal tract. Therefore, the 
specific aims of this project are as follows: 
Aim 1: Extraction and Isolation (Chapter 2). To identify the chemical constituents of noni fruit 
extract contributing to its inhibitory effect against bacterial β-glucuronidase, through 
phytochemical extraction and isolation guided by bioactive assay. 
Aim 2: Elucidation of Chemical Structures (Chapter 3). To elucidate chemical structures of 
purified compounds using HRMS and 1D, 2D-NMR, and establish their absolute configurations 
by comparing experimental and calculated ECD spectra.  
Aim 3: Evaluation of Inhibitory Activities (Chapter 4). To measure inhibitory activities of 
purified compounds against bacterial β-glucuronidase and digestive enzymes, evaluate their 







CHAPTER 2 Isolation of Bioactive Compounds from Noni Fruits 
Natural products are chemical substances or compounds isolated from living organism, 
including plants, animals, fungi and microorganisms (45, 46). They are produced by the primary 
or secondary metabolisms of organism. Primary metabolites are essential organic molecules for 
the growth, development and reproduction of organism, such as nucleic acids, amino acids, fatty 
acids and sugars. They are necessary building blocks to make life sustaining macromolecules 
including DNA, proteins, lipids and carbohydrates. Secondary metabolites are not directly 
involved in these essential processes, but they have ecological function that increase the 
competitiveness of the organism to deal with very complicated and varied environment. They are 
much more organism-dependent, and present great diversities in chemical structures and biological 
functions. Such as flavonoids, phenolics, tannins and alkaloids, they have lots of structural 
subtypes and are among the most bioactive compounds (47). Therefore, natural products of 
secondary metabolites have been widely studied and developed for the application in food, spices, 
traditional and modern medicines (48, 49). Like antibacterial drug penicillins from Penicillium 
chrysogenum, opioid analgesic drug morphine from Papaver somniferum, and artemisinin 
(qinghaosu) against Plasmodium falciparum malaria, natural products contribute greatly to the 
history and landscape of new molecular entities (NMEs) (50). By the end of 2013, over one-third 
(38%) of NMEs approved by U.S. Food and Drug Administration (FDA) are natural products or 
their derivatives (51). 
In our preliminary experiment, the bioactive extract used was also a mixture of secondary 
metabolites from noni fruits. Therefore, the first priority of this project was to isolate the mixture 







2.1. Introduction of Noni (Morinda citrifolia) 
Morinda citrifolia L. (Rubiaceae) (Figure 4) is a small evergreen tree that is originated in 
South Asia, but now is widely distributed across the tropical countries of the world, including 
Polynesia, Northeastern Australia and the Caribbean (52). The most popular name “noni” is from 
Hawaiian and Tahitian islands (53), whereas it is called Indian mulberry in India, mengkudu in 
Malaysians and painkiller bush in the Caribbean (54), and the fruits are also known as cheese fruit 
in Australia (55). 
 
Figure 4. Fruits and flowers of Noni (Morinda citrifolia) 
 
All parts of noni have been traditionally used for medicinal purposes, including the roots, 
bark, leaves, seeds and fruits (52). Modern research on noni might be incentivized by the report 
from the Pacific Tropical Garden Bulletin in 1985, which suggested a number of potential health 
benefits for noni juice, such as treating high blood pressure, menstrual cramps, arthritis and many 
others (55, 56). Since the 1990s, noni has become a popular dietary supplement in the USA (57). 






the predominant form in the market, and it could be pasteurized, fermented, or flavored by other 
fruit juice to make the product more palatable (58). The noni fruit juice was approved by the 
European commission in 2003 as well, and the use of noni has been broadly available in stores and 
on the Internet (52). 
2.1.1. Nutritional content and chemical constituents of noni 
Nutritional content of M. citrifolia have been evaluated for health utilization. The leaves 
were considered as an abundant source of carotenoids by Aalbersberg et al. (59). Peerzada et al. 
found that noni fruits from Australia contain up to 2012 mg of potassium and 158 mg of vitamin 
C per 100 g of dry weight (60). The noni fruit juice was also shown to possess relatively high 
levels of potassium (30-150 ppm) and vitamin C (30-155 mg/kg) (61). Bui et al. analyzed the 
saccharide content of noni fruits collected in Vietnam, it was found that the monosaccharides were 
mostly galactose, arabinose, rhamnose and galacturonic acid, while polysaccharides were mainly 
pectic polysaccharides, such as arabinan, pectins homogalacturonan, and type Ⅰ and Ⅱ 
arabinogalactans (62).  
The earliest research on chemical constituents of M. citrifolia could be traced back to the 
investigation on noni roots, heartwood and cell culture, which were reported by Simonsen et al. in 
1918 and 1920 (63, 64). After 50 years of silence, the phytochemical studies of these parts of noni, 
and also seeds and flowers, emerged again during 1970s and 1980s (52). Since 1990s, the 
phytochemical investigation on noni have been focused on the leaves and fruits (52). Generally, 
the roots were found predominated by anthraquinones and anthraquinone glycosides (65), while 
some iridoids, triterpenes and flavonoids were isolated from leaves (66). The plant cell cultures 






along with the commercial application of fruit juice as nutritional supplement (55). Up to date, 
more than 200 chemical constituents have been reported from different parts of M. citrifolia, 
including fatty acid glycosides, alcohol glycosides, iridoids and iridoid glycosides, lignans, 
neolignans, anthraquinones and anthraquinone glycosides, flavonoids, phenylpropanoids, 
triterpenoids and others (52, 55, 67). Their chemical structures were primarily identified by nuclear 
magnetic resonance (NMR) spectroscopy and mass spectrometry (52). 
2.1.2. Biological activities and safety of noni 
The biological activities of both extracts and pure compounds of M. citrifolia have been 
comprehensively evaluated in vitro and in vivo. The investigated parts include the leaves, roots, 
seeds, and particularly the fruits (52, 55). Their pharmacological activities mainly involve in anti-
microbial (68), anti-fungus (69), anti-virus (70), anti-oxidation (71), anti-inflammation (72), anti-
obesity (73), anti-diabetes (74), anti-arthritic (75), anti-tubercular (76), anti-pigmentation (77), 
analgesic (78), and so on. Especially, the anticancer effects of M. citrifolia have attracted relative 
more attention (79). The juice or extracts from noni fruits have been shown antiproliferative effects 
against various tumor cells (80), reducing mammary tumor growth in mice (81), inducing 
apoptosis in human cervical cancer cells and on the Ehrlich ascites tumor in Balb‐c mice (82, 83). 
Pure compounds isolated from M. citrifolia proved to contribute to the overall anti-tumor activities 
of noni extracts. Masuda et al. revealed that the two lignans, 3,3'-bisdemethylpinoresinol and 
americanin A, were active constituents of noni seeds to inhibit melanogenesis in murine B16 
melanoma cells (84). Two glycosides from noni fruit juice could inhibit AP-1 transactivation and 
cell transformation in the mouse epidermal JB6 cell line (85). The anthraquinones from noni roots 






polysaccharide‐rich substance from noni fruit juice was also found having antitumor activity (88, 
89). 
It is worth noting that several clinical trials have been conducted for M. citrifolia (79). In 
a randomized, double blinded and placebo-controlled trial, Prapaitrakool et al. showed that an 
extract from M. citrifolia Linn. fruits effectively reduced the incidence of early postoperative 
nausea (0-6 h) from 80% to 48% (P = 0.04), at the dose level of 600 mg and taken orally 1 hour 
before surgery (90). In a Phase Ⅰ clinical trial aiming to determine noni dose for patients with 
advanced cancer, Issell et al. suggested that a dose of four capsules four times per day (8 g) could 
be appropriate for Phase Ⅱ trial in terms of quality of life measures (91). Noni has been used to 
treat women with primary dysmenorrhea, but show no reduction effects on menstrual pain or 
bleeding comparing to placebo (72). A combination of noni powder and anti-rheumatism therapy 
showed effect to treat a case of psoriasis (92), another noni supplements combined with calorie 
restriction and exercise interventions resulted in body weight loss and fat mass decrease for 
overweight participants (73). However, the biological effects and contribution of noni were not 
clarified in these combination studies, which need to be verified by further experiment. 
A number of animal studies have indicated that noni administration are nontoxic to the rats 
(93, 94). However, several cases of plausible toxicity have been reported for human who consumed 
noni fruit juice (52). The elevated potassium levels were reported for a patient with chronic renal 
insufficiency, but lacking detailed information on how much noni juice the patient took (95). Since 
recommended dose of 1-3 oz per day would not cause hyperkalaemia, it is necessary to confirmed 
whether the patient consumed a does more than recommendation (52). Another concern of noni 






significant increasing in liver enzymes when taking noni juice, such as transaminases and lactate 
dehydrogenase, and the levels of these liver enzymes returned back to normal levels after 
interruption of noni juice intake (96-98). However, most of these patients were simultaneously 
taking other herbs or medicines, the observed hepatotoxicity could not be directly linked with noni 
juice without further evidences. A possible correlation between anthraquinones and hepatotoxicity 
were suggested, however, the content of this constitutes was relatively high in noni roots, while 
extremely low in noni fruits (55). Thus, it is not reasonable to deduce the toxicity of noni fruit 
juice by anthraquinones. On the contrast, West et al. listed dietary utilization of noni and 
summarized previous animal and human studies on noni, which gave a general conclusion that 
noni is safe for dietary supplementation (93). 
2.2. Isolation and Purification 
For the isolation of natural products, the normally used methods include extraction, 
precipitation, adsorption, and especially chromatography (46). Each chromatographic method 
consists of a stationary phase that doesn’t move and a mobile phase that does move (99, 100). The 
mobile phase can be organic solvents, water or gas, which carries the mixture of sample to go 
through the stationary phase. During the process, different compounds interact differently with the 
two phases, and move forward with different velocities, which result in different retention 
properties and chromatographic separation. Chromatographic methods could be divided into many 
subtypes in terms of separation mechanism, phase condition and shape of chromatographic bed 
(Table 2). Of which, the thin layer chromatography (TLC) is often used to predict or evaluate 
separation effects, while column chromatography is primarily utilized to implement the practical 






used methods of column chromatography include normal phase (silica gel), reverse phase (ODS, 
C18), size exclusion (Sephadex LH-20) and so on. In order to obtain finer separation, the specific 
stationary materials, mobile phase solvents and column size should be carefully optimized based 
on the physical and chemical characteristics of target samples. It is worth noting that the semi-
preparative HPLC system combines high-efficient separation, on-line detection and analysis, and 
even automatic sample collector together, which make it a widely used powerful technique for the 
separation of samples that are difficult to be isolated by normal methods (analogues) and 
compounds with small amounts (about 5 mg or less) (102). 
Table 2. Classification of chromatography used for the isolation of natural products 
Technique Format Stationary Phase Mobile Phase Separation Mechanism 





planar silica, cellulose, ion-
exchange resin, 
controlled porosity solid 
liquid adsorption (partition, 
ion-exchange, size-
exclusion) 






























2.2.1. Equipment and materials  
In this study, semi-preparative HPLC was carried out on a Hitachi LaChrom Elite liquid 
chromatograph system (Tokyo, Japan) equipped with L-2130 pump and L-2455 detector, and a 
Waters XBridge BEH300 Prep C18 column (250 mm × 19 mm i.d., 10 μm; Milford, MA, USA). 






silica gel (40-60 μm, 60 A; Acros Organics, Morris Plains, NJ, USA), and Sephadex LH-20 (GE 
Healthcare, Uppsala, Sweden) were used for column chromatography fractionation. 
Noni fruit powder was purchased from Starwest Botanicals, Inc. (Sacramento, CA, USA) 
with lot numbers 58868 and 63285 (Figure 5). It was collected from India and identified as 
Morinda citrifolia L. (Rubiaceae). The packages were stored in dark at 4 °C before use. A voucher 
specimen (BS2015-029) was deposited in our laboratory, Department of Nutrition and Food 
Science, Wayne State University. 
 
Figure 5. Noni (Morinda citrifolia) fruit powder used in this study 
 
2.2.2. Isolation procedures 
The isolation of active compounds from noni fruit extract was guided by inhibitory assay 
of bacterial β-glucuronidase (Figure 6). After each step of separation, only the bioactive fractions 







Figure 6. The isolation process of bioactive compounds from Noni fruit powder 
 
Specifically, noni fruit powder (13.2 kg) was extracted with 50% acetone/water twice (at 
ratio of 10 L/kg and 8 L/kg, respectively) at room temperature with stirring. The combined extracts 
were concentrated until acetone was completely removed, then the water phase was subjected to 
separation over a HP-20 resin column (11 × 70 cm), and eluted with 0%, 30%, 50%, 70% and 100% 
ethanol/water, sequentially. After being concentrated, 29 g of 70% ethanol/water extract (active 






with CH2Cl2-MeOH (1:0, 20:1, 10:1, 6:1, 4:1, 1:1 and 0:1, v/v), to yield five sub-fractions (F-1 to 
5). Active fraction F-3 (10 g) was then separated on a silica gel containing column with CH2Cl2-
MeOH (20:1, 10:1, 5:1, and 2:1, v/v) to obtain four sub-fractions. Active subfraction F-3-2 (2.7 g) 
was further purified by a Sephadex LH-20 column chromatography (CH2Cl2-MeOH, 1:1, v/v) to 
afford two main sub-fractions. Active fraction F-3-2-2 (800 mg) was purified by semi-preparative 
HPLC (CH3CN-H2O, 1:20, v/v; 4 mL/min; detector wavelength at 230 nm), to obtain four purified 
active compounds, 1 (31.93 min, 12 mg), 2 (48.19 min, 11 mg), 3 (69.50 min, 33 mg), and 4 (83.42 
min, 87 mg) (Figure 7). 
 








CHAPTER 3 Elucidation of Chemical Structures 
Chemical structure refers to the spatial arrangement of atoms in a molecule and the 
chemical bonds that connect atoms together. Carbon and hydrogen are the elementary atoms of 
organic compounds or natural products. Most of natural products also contain oxygen, and some 
may include nitrogen, phosphorous, sulfur or the halogens. These atoms are mainly linked by 
covalence bonds that share electron pairs in the forms of single, double or triple bonds. In the 
history, the chemical structures of natural products could not be described until the advent of 
structural theory based on the frameworks of Kekulé (1857), Couper (1858) and Butlerov (1859), 
and the foundation of stereochemistry by Le Bel (1874) and van’t Hoff (1875) (103).   
Early procedure of structural elucidation is very complicated (46). It was often started with 
the measurement of sharp melting point to confirm the purity, and elemental analysis to decide 
molecular formula. It was followed by a combination of derivatization and degradation reactions 
to deduce functional groups and fragments. Eventually, the proposed structure needs to be 
validated by known chemical synthesis. Consequently, a large amount of sample (grams) was 
required for destructive reactions, and it always took several or even tens of years to figure out a 
specific structure. For example, the structures of morphine and strychnine were determined 118 
and 127 years after they were firstly isolated, respectively (104, 105). Until 1960s, structural 
elucidation was developed into a new era that is dominated by spectroscopic techniques and X-ray 
crystallography (103). Up to date, frequently used spectroscopic methods include nuclear magnetic 
resonance (NMR), which contains 1H-, 13C-, and 2D-NMR, mass spectrometry (MS), ultraviolet 
(UV) and infrared (IR). In addition, a lot of new methods have been developed and applied in this 
area, such as 3D-NMR, solid-state NMR and computer-assisted structure elucidation (106, 107). 






reduced to several days or even minutes, sample amount required could be several milligrams, and 
it is much easier to solve the structures of complicated natural products (108). 
Absolute configuration is a concept of stereochemistry, it refers to the spatial arrangement 
of the atoms of a chiral molecular entity, and could be described in R (Rectus) or S (Sinister) 
(Figure 8) (109). Theoretically, if a chiral molecule contains number n (≥ 1) of chiral center atom(s) 
(usually carbon), it can exist in any of the 2n of absolute configurations. In other words, it has 2n-1 
pair(s) of possible enantiomers, and each pair of enantiomers has mirror-image structures. 
However, as natural products of living organisms, all discovered primary metabolites (L-amino 
acids, nucleotides and monosaccharides) and about 80% of known secondary metabolites are chiral 
non-racemic or asymmetric enantiopure molecules (110). Besides, it is found that two enantiomers 
of a chiral molecule always possess totally different biological activities and pharmacological 
behaviors, which may due to their biological receptors of organisms that are already chiral in 
structures (111). Among the new molecular entities approved by the FDA, chiral drugs have 
increased from 30-40% in the 1990s to over 60% of in the 2000s (112). Therefore, determining 
the absolute configuration of a chiral molecule has become an important, but also challenging area 
in the chemistry of natural products (110, 113).  
 
Figure 8. Description of absolute configurations for a pair of enantiomers, A, B, C, D represent 






Single crystal X-ray diffraction analysis has been considered the most accurate and 
important method to determine absolute configuration. However, the measurement requires high 
quality of crystal, which limits its application for many natural products that are difficult to culture 
crystal. The modified Mosher’s NMR method is another powerful tool to decide absolute 
configuration. But it is not easy to find suitable functional groups (normally OH and NH2) in many 
molecules to conduct chiral derivatization. Chiroptical methods are based on the optical 
interactions between chiral non-racemic compounds and the right and left circularly polarized light. 
Currently, the primary chiroptical spectroscopy includes optical rotation (OR), optical rotatory 
dispersion (ORD), electronic circular dichroism (ECD) and vibrational circular dichroism (VCD). 
Especially, ECD and VCD have been more frequently used for determining absolute 
configurations of natural products, due to their less demand on structural properties, sample 
amount and status (114). In practical use, absolute configuration of a specific compound is 
established by comparing its experimental circular dichroism (CD) spectrum to the CD spectra of 
appropriate analogues with known absolute configuration. However, it is hard to find comparable 
analogues for most of novel natural products. In this case, calculated CD spectra have become a 
credible alternative along with the development of computational chemistry (115).  
In this study, the structures of four purified compounds were elucidated through the 
combination of HRESIMS, MNR and UV. Their absolute configurations were established with the 
assistance of ECD calculation, because of limited amounts, difficulty of culturing single crystal 








3.1. Spectroscopic Data Acquisition 
The optical rotations were measured in MeOH on an Autopol Ⅲ automatic polarimeter 
(Rudolph Research Analytical, Hackettstown, NJ, USA) with a sodium lamp operating at 589 nm. 
ECD spectra in solvent methanol were recorded on a JASCO J-815 spectrometer (Tokyo, Japan). 
NMR spectra were obtained from Varian VNMRS-500 MHz (Palo Alto, CA, USA) and Agilent 
DD2-600 MHz (for optimized HMBC spectra; Santa Clara, CA, USA) spectrometers, with δ in 
ppm related to TMS, and J in Hz. HRESIMS analyses were performed on Thermo Scientific LTQ 
Orbitrap XL Mass Spectrometer (San Jose, CA, USA).  
(7S,8S,7'R,8'R)-Isoamericanol B (1). Brown amorphous powder; [α]
22
D
 - 8.0 (c 0.05, MeOH); 
UV (MeOH) λmax (log ε) 206 (5.01), 230 (sh) (4.52), 270 (4.12), 287 (sh) (4.05), 305 (sh) (3.57), 
315 (sh) (3.36) nm; ECD (MeOH) λmax (Δε) 205 (+ 2.58), 211 (- 7.49), 218 (+ 0.36), 226 (- 1.31), 
241 (+ 0.14), 288 (- 1.50) nm; 1H (500 MHz) and 13C (125 MHz) NMR (CD3OD) data, see Table 
3; HRESIMS m/z 493.1491 [M - H]- (calcd for C27H25O9, 493.1493, Figure A1). 
Americanol B (2). Brown amorphous powder; [α]
22
D
 + 2.0 (c 0.05, MeOH); UV (MeOH) 
λmax (log ε) 206 (5.00), 230 (sh) (4.54), 270 (4.16), 287 (sh) (4.10), 305 (sh) (3.65), 315 (sh) (3.43) 
nm; ECD (MeOH) λmax (Δε) 198 (+ 1.53), 206 (- 14.7), 219 (- 0.29), 225 (- 1.51), 245 (- 0.09), 288 
(- 1.96) nm; 1H (500 MHz) and 13C (125 MHz) NMR (CD3OD) data, see Table 3; HRESIMS m/z 
493.1486 [M - H]- (calcd for C27H25O9, 493.1493, Figure A2). 
Moricitrin A (3). Brown amorphous powder; [α]
22
D
 + 2.0 (c 0.05, MeOH); UV (MeOH) λmax 
(log ε) 206 (5.06), 230 (sh) (4.40), 283 (4.00), 310 (sh) (2.97) nm; ECD (MeOH) λmax (Δε) 195 (+ 






nm; 1H (500 MHz) and 13C (125 MHz) NMR (CD3OD) data, see Table 3; HRESIMS m/z 657.1952 
[M - H]- (calcd for C36H33O12, 657.1967, Figure A3). 
Moricitrin B (4). Brown amorphous powder; [α]
22
D
 - 8.0 (c 0.05, MeOH); UV (MeOH) λmax 
(log ε) 206 (5.06), 230 (sh) (4.42), 283 (4.03), 310 (sh) (3.08) nm; ECD (MeOH) λmax (Δε) 198 (+ 
10.64), 210 (- 6.92), 221 (- 0.61), 229 (- 1.30), 233 (- 0.17), 239 (- 1.42), 245 (- 0.53), 283 (- 2.47) 
nm; 1H (500 MHz) and 13C (125 MHz) NMR (CD3OD) data, see Table 3; HRESIMS m/z 657.1954 






Table 3. 1H and 13C NMR Spectroscopic Data of Compounds 1-4 in CD3OD
 
 1 2 3 4 
position δC, type δH (J in Hz) δC, type δH (J in Hz) δC, type δH (J in Hz) δC, type δH (J in Hz) 
1 129.4, C  129.4, C  135.5, C  135.6, C  
2 115.5, CH 6.87, d (2.3) 115.5, CH 6.87, d (2.1) 115.8, CH 6.89, m 115.8, CH 6.96, m 
3 146.6, C  146.6, C  145.2, C   144.4, C  
4 147.1, C  147.2, C  144.4, C  144.8, C  
5 116.3, CH 6.81, m 116.4, CH 6.82, m      117.9, CH 6.91, d (8.3) 118.0, CH 6.92, d (8.3) 
6 120.4, CH 6.78, m 120.4, CH  6.77, m 120.3, CH 6.85, m 120.1, CH 6.83, m 
7 77.6, CH 4.84, d (8.2) 77.6, CH 4.83, d (8.1) 87.0, CH 4.66, brs 87.0, CH 4.67, brs 
8 79.9, CH 4.03, m 79.8, CH 4.01, m 55.3, CH 3.04, brs 55.4, CH 3.06, brs 
9 62.0, CH2 3.49, m 
3.70, m 
 
62.1, CH2 3.50, m 
3.70, m 
 
72.7, CH2 3.79, m 
4.18, m 
72.7, CH2 3.81, m 
4.19, m 
1' 131.3, C  131.3, C  135.5, C  135.6, C  
2' 117.2, CH 7.01, m 117.2, CH 7.06, m 115.8, CH 6.89, m 115.8, CH 6.96, m 
3' 145.4, C  145.8, C  145.2, C   144.4, C  
4' 145.4, C  145.0, C  144.4, C  144.8, C  
5' 118.1, CH 7.02, m 118.1, CH 6.93, m 117.9, CH 6.91, d (8.3) 118.0, CH 6.92, d (8.3) 
6' 121.8, CH 6.97, m 121.6, CH 6.93, m 120.3, CH 6.85, m 120.1, CH 6.83, m 
7' 77.3, CH 4.90, m 77.3, CH 4.91, m 87.0, CH 4.66, brs 87.0, CH 4.67, brs 
8' 79.9, CH 4.03, m 79.8, CH 4.01, m 55.3, CH 3.04, brs 55.4, CH 3.06, brs 
9' 62.0, CH2 3.50, m 
3.70, m 
62.1, CH2 3.50, m 
3.70, m 
72.7, CH2 3.79, m 
4.18, m 
72.7, CH2 3.81, m 
4.19, m 
1" 132.0, C  132.2, C  129.5, C  129.5, C  
2" 115.5, CH 6.97, d (2.3) 115.5, CH 7.03, d (1.8) 115.6, CH 6.85, m 115.5, CH 6.84. m 
3" 144.5, C  144.8, C  146.6, C  146.6, C  
4" 145.1, C  144.8, C  147.1, C  147.1, C  
5" 117.9, CH 6.90, m 118.0, CH 6.87, m 116.4, CH 6.80, d (8.0) 116.3, CH 6.79, m 
6" 120.9, CH 6.92, m 120.8, CH 6.91, m 120.4, CH 6.74, dd 
(8.0, 2.0) 
120.4, CH 6.74, m 
7" 131.3, CH 6.49, d 
(15.3) 
131.3, CH 6.51, d 
(16.0) 
77.6, CH 4.77, d (8.0) 77.6, CH 4.79, d (7.9) 
8" 128.2, CH 6.21, m 128.2, CH 6.22, dt 
(16.0, 5.8) 
79.9, CH 3.97, m 79.9, CH 3.98, m 








1'"     129.5, C  129.5, C  
2'"     115.6, CH 6.85, m 115.5, CH 6.84. m 
3'"     146.6, C  146.6, C  
4'"     147.1, C  147.1, C  
5'"     116.4, CH 6.80, d (8.0) 116.3, CH 6.79, m 
6'"     120.4, CH 6.74, dd 
(8.0, 2.0) 
120.4, CH 6.74, m 
7'"     77.6, CH 4.77, d (8.0) 77.6, CH 4.79, d (7.9) 
8'"     79.9, CH 3.97, m 79.9, CH 3.98, m 














3.2. ECD Computation  
3.2.1. Computational chemistry and its application in CD calculation 
Computational chemistry is founded on the development of theoretical chemistry and 
efficient computer programs (116). It can be used to calculate structures and properties of 
molecules, such as relative energy, dipole moment, vibrational frequency, charge distribution, 
reactivity and spectroscopic quantity. The aims of computational chemistry are to analyze 
complicated experimental data, predict new reactions or molecules, or predict spectroscopies. 
There are two types of methods to model molecular systems according to starting point theory. 
One type is classical method based on the laws of classical physics, which treat atoms as spheres 
and bonds as springs, while ignoring electronic distribution in molecules. Classical methods 
primarily contain molecular mechanics (MM) and molecular dynamics (MD). They are 
implemented through force fields that refer to functional forms and parameter sets of calculation. 
Many force fields have been designed for different simulation purposes, such as AMBER and 
CHSRMM for molecular dynamics of macromolecules, MM2 for conformational analysis, and 
MMFF (Merck Molecular Force Field) for a broad range of molecules (117). Another type is 
quantum chemistry methods based on quantum mechanics (QM), which describe electronic 
distribution of molecules using Schrödinger’s equation. Complete solution of Schrödinger’s 
equation can provide an exact description of electronic structure of a molecule. However, up to 
data, the equation can only be exactly solved for hydrogen atom, but not for any other atomic or 
molecular systems involving motions of three or more particles. Alternatively, approximate 
solutions have been developed for practical application, which include ab initio methods (Hartree-
Fock, MP2), semi-empirical methods (AM1, MNDO, PM3), and density-functional theory (DFT) 






the calculation of Hartree-Fock (HF) or DFT. Commonly used basis sets include B3LYP, 6-31G, 
6-311G, cc-pVDZ and so on (117).  
Molecular mechanics (MM) is restricted to describe equilibrium structures and 
conformations. It could be used to minimize energies, study molecular motions, and search stable 
conformations. While quantum mechanics additionally provides information of non-equilibrium 
forms, it is suitable to calculate molecular orbital energies, heat formation of a conformation, 
dipole moment and transition-state geometries and energies (116, 118). Quantum mechanics has 
more computing power than molecular mechanics, but it is more computational expensive (time) 
and only limited to hundreds of atoms. Selection of specific methods is dependent on calculation 
goals, and the trade-off between accuracy and computational expense. 
The procedure of CD computation primarily consists of conformational analysis and DFT 
or TDDFT calculation (117). Because of rotation about single bonds, a compound presents in 
multiple conformers that are rapidly equilibrating. The population distributions of conformers are 
determined by their relative free energies, a conformer with lower free energy is more stable and 
has higher population. The interconversion rate between isomers are decided by energy barriers, 
the higher barrier means lower interconversion rate. CD spectrum is sensitive to conformation, it 
is a spectral combination of all conformers following Boltzmann distribution. Therefore, the first 
step is searching for stable conformers with lower free energies that contribute the most to the 
dynamic equilibrium, by molecular mechanics force fields. Obtained stable conformers could be 
optimized using less expensive basis sets of DFT calculation. Then, each stable conformer is 
calculated for CD spectrum. DFT methods is often used for VCD computation that involves ground 






TDDFT method to calculate oscillator strength that simulate UV curve, and rotatory strength that 
predict ECD curve (115). Since CD spectrum of a compound is experimentally measured in the 
form of solution, the effects of solvent need to be taken into account for computation. Either 
explicit or implicit solvation models could be utilized to simulate solvent effects. The implicit 
solvation model treats solvent as a continuum medium, particularly the polarizable continuum 
model (PCM) has been most commonly used for CD calculation (117). 
3.2.2. ECD calculation of compounds 1-4 
ECD and VCD are different in measuring mechanisms, application requirements and 
calculation methods (Table 4) (119, 120). VCD spectrum doesn’t rely on the existence of 
chromophore groups in a molecule and has a relatively broader spectrum range, which shows a 
prospect of wide application. However, VCD is a relative young technique that the first 
commercial instrument was introduced in 1997 (121), and usable theories of spectrum 
interpretation have not been established. In addition, VCD measurement demand a relatively high 
sample concentration (20-50 mg/mL) (110). These are still restrictions for VCD application 
currently. While ECD has been used for more than five decades, there are plenty of practical 
accumulation, and many semi-empirical rules and exciton chirality methods have been developed 
to interpret ECD spectra (110). With the advantage of less requirement on sample amount, ECD 









Table 4. Comparison between ECD and VCD 
 ECD VCD 
Radiation ultraviolet and visible light infrared (IR) region 
Induced Transition electronic vibrational 
Sample Amount 1-10 µg/mL 20-50 mg/mL 
Chromophore Group needed not necessary 
Calculation excitation state TDDFT ground state DFT 
 
Compounds 1-4 have relatively small amounts, but possess chromophore groups, which 
makes ECD computation a feasible choice to determine their absolute configurations. Since each 
compound has two pairs of possible enantiomers, and ECD spectra of paired enantiomers are 
theoretically symmetric, only one enantiomer of each pair was calculated using quantum-
mechanical methods (Table 5).  
Table 5. Possible enantiomers of compounds 1-4 
Calculated enantiomer Paired enantiomer 
1a (7S, 8S, 7'R, 8'R) 
1b (7R, 8R, 7'R, 8'R)  
1a' (7R, 8R, 7'S, 8'S)  
1b' (7S, 8S, 7'S, 8'S) 
2a (7S, 8S, 7'R, 8'R) 
2b (7R, 8R, 7'R, 8'R) 
2a' (7R, 8R, 7'S, 8'S) 
2b' (7S, 8S, 7'S, 8'S) 
3a (7S, 8R, 7'S, 8'R, 7"S, 8"S, 7'"S, 8'"S) 
3b (7S, 8R, 7'S, 8'R, 7"R, 8"R, 7'"R, 8'"R)  
3a' (7R, 8S, 7'R, 8'S, 7"R, 8"R, 7'"R, 8'"R) 
3b' (7R, 8S, 7'R, 8'S, 7"S, 8"S, 7'"S, 8'"S) 
4a (7S, 8R, 7'S, 8'R, 7"S, 8"S, 7'"S, 8'"S) 
4b (7S, 8R, 7'S, 8'R, 7"R, 8"R, 7'"R, 8'"R)  
4a' (7R, 8S, 7'R, 8'S, 7"R, 8"R, 7'"R, 8'"R) 
4b' (7R, 8S, 7'R, 8'S, 7"S, 8"S, 7'"S, 8'"S) 
 
In this investigation, conformational analysis was performed by CONFLEX 8 (Revision A, 
Tokyo, Japan), DFT (density functional theory) geometry optimization and TDDFT (time-






CT, USA), and the calculated UV and ECD spectra were plotted using SpecDis (Version 1.71, 
Berlin, Germany) (115). 
 
Figure 9. Determination of absolute configuration by ECD calculation 
 
Specifically shown in Figure 9, force field MMFF94S was used for conformer searching 
of each configuration, and energy window was set at 3 kcal/mol. The obtained stable conformers 
with populations above 0.5% or 1.0% (Table 6) were optimized further by a DFT method at the 
B3LYP/6-31G(d) level, with solvent effects of methanol included using a polarizable continuum 
model (PCM) (122). Thereafter, the dominant conformers possessing relative energies less than 
0.8 or 2.0 kcal/mol were selected (Table 6), and their TDDFT calculations were performed at the 
APFD/6-311+g (2d, p) level with PCM (methanol) (123). The spectra obtained of the conformers 
were averaged by SpecDis according to their Boltzmann distributions, which generate theoretical 
ECD (Figure 14, 17, 20 and 23) and UV (Figure 10) spectra of each configuration. UV spectra 






Table 6. Criteria of Conformer Selection for DFT Optimization and TDDFT Calculation of 
Model Configurations of Compounds 1-4 
configuration conformer for DFT optimization 
(population, number) 
conformer for TDDFT calculation 
(relative energy in kcal/mol, number) 
1a > 0.5%, 38 < 0.8, 17 
1b > 0.5%, 28 < 0.8, 13 
2a > 0.5%, 30 < 0.8, 16 
2b > 0.5%, 32 < 0.8, 21 
3a > 1.0%, 9 < 2.0, 2 
3b > 1.0%, 5 < 2.0, 3 
4a > 1.0%, 19 < 2.0, 18 






Figure 10. Experimental (solid lines) and calculated (dashed lines) UV spectra of compounds 1-








3.3. Structural Elucidation 
The four compounds were elucidated as two sesquineolignans, (7S,8S,7'R,8'R)-
isoamericanol B (1) and americanol B (2), and two dineolignans, moricitrin A (3) and moricitrin 
B (4) (Figure 11). Of which, compounds 2-4 are new structures, and the absolute configuration of 
1 was assigned for the first time. 
           
1 (= 1a, 7S, 8S, 7'R, 8'R)                                             2 (= 2a', 7R, 8R, 7'S, 8'S) 
 
 
3 (= 3a', 7R, 8S, 7'R, 8'S, 7"R, 8"R, 7'"R, 8'"R)         4 (= 4b', 7R, 8S, 7'R, 8'S, 7"S, 8"S, 7'"S, 8'"S) 








3.3.1. (7S,8S,7'R,8'R)-Isoamericanol B 




8.0 (c 0.05, MeOH). Its molecular formula was determined as C27H26O9 by analyzing the 
HRESIMS peak at m/z 493.1491 [M - H]- (calcd for 493.1493) and 1H and 13C NMR spectroscopic 
data (Table 1). Compound 1 was identified as a known sesquineolignan, isoamericanol B1 or B2, 
by further comparing its NMR data with the previously reported structures (124). The paired 
signals at δ 144.5 (C-3") and 145.1(C-4") in the 13C NMR spectrum suggested an isoamericanol-
type structure with an additional caffeoyl alcohol substitution. The isoamericanol-type moiety was 
confirmed by the observation of a diagnostic correlation between H-9'b (δ 3.50) and C-4" after 
optimizing the proton-carbon coupling constant of HMBC to 3 Hz (Figure 12). Two signals at δ 
145.4 (C-3' and C-4') suggested that the additional hydroxymethyl group is located on the same 
side of the molecule as C-4', and the dihydroxy-phenyl group is close to C-3'. The coupling 
constant J7",8" = 15.3 Hz suggested an E-configuration at the double bond of C-7" and C-8". The 
large coupling constant between H-7 and H-8 (J = 8.2 Hz) indicated a trans substitution at C-7 and 
C-8 (125). All the signals of 1 were assigned with the assistance of HSQC, COSY and HMBC 
NMR spectra. 
 







ECD spectra have been used extensively to establish the absolute configuration of natural 
product structures based on relative configurations. However, ROESY correlations between H-
7/H-8 and H-7'/H-8' were not detectable in this investigation due to the long distances between 
these two steric centers (6.7-8.0 Å, Figure 13), making it impossible to determine the relative 
configurations of H-7 and H-8 based on the ROESY spectrum. This is consistent with the previous 
report on elucidating the same type of compounds with this technique (124).  
 
 
                  1 
Figure 13. Distances between protons of steric centers for compounds 1 (energy minimized by 
MM2 force field) 
 
Theoretically, possible trans substitutions of H-7 and H-8 generate two pairs of 
enantiomers, namely, 1a (7S, 8S, 7'R, 8'R) and 1a' (7R, 8R, 7'S, 8'S), 1b (7R, 8R, 7'R, 8'R) and 1b' 
(7S, 8S, 7'S, 8'S). Within this small scope, it was hypothesized that each configuration possesses a 
unique ECD spectrum. Hence, ECD spectra were measured to determine their relative and absolute 
configurations simultaneously. The ECD spectra of 1a and 1b were calculated. As shown in Figure 
proton distance 
H-7 to H-7' 7.7 Å 
H-7 to H-8' 6.7 Å 
H-8 to H-7' 8.0 Å 







14, the experimental ECD spectrum matched best with 1a, suggesting that 1 has the same absolute 
configuration as 1a (7S, 8S, 7'R, 8'R). Therefore, the structure of 1 was determined as (7"E)-
(7S,8S,7'R,8'R)-3,4,9,9',9"-pentahydroxy-7,3':7',3"-diepoxy-8,4':8',4"-bisoxysesquineolign-7"-
ene, namely, (7S,8S,7'R,8'R)-isoamericanol B. This represents the first time that the absolute 
configuration of this compound has been established. 
 
Figure 14. Experimental and calculated ECD spectra of compound 1 in MeOH, a and b 
represent the model configurations of each compound 
 
3.3.2. Americanol B 




2.0 (c 0.05, MeOH). Its molecular formula was determined as C27H26O9 by analyzing the 
HRESIMS peak at m/z 493.1486 [M - H]- (calcd for 493.1493) and its 1H and 13C NMR data (Table 
1). By comparing its NMR data to those of similar structures isoamericanol C1 or C2 (124), the 






located on the same side of the molecule as C-3', and a dihydroxy-phenyl group being on the same 
side as C-4'. However, different chemical shifts at δC 144.8 (C-3" and C-4") suggested a different 
substitution for the hydroxypropenyl group in compound 2. Weak correlations from H-9' (δ 3.50) 
and H-7' to the signals of δC 144.8 were observed in the HMBC spectrum with the proton-carbon 
coupling constant optimized as 3 Hz (Figure 15), however, the signals at δC 144.8 were assigned 
to both C-3" and C-4", thus, these correlations could not be used to distinguish the different 
substitutions. Nevertheless, the characteristics of C-3" and C-4" were identical to those of reported 
C-3' and C-4' in americanol A (53, 124, 126). Therefore, the hydroxypropenyl group was proposed 
as being located on the same side of the molecule as C-8' in compound 2. The coupling constant 
J7",8" = 16.0 Hz revealed an E-configuration at C-7" and C-8", J7,8 = 8.1 Hz suggested the trans 
orientations of H-7 and H-8. All signals were assigned with the assistance of HSQC, COSY and 
HMBC NMR spectra. 
 
Figure 15. Key COSY (bold lines) and HMBC (blue arrows) correlations of compound 2 
 
Compound 2 also has two pairs of trans enantiomers, 2a (7S, 8S, 7'R, 8'R) and 2a' (7R, 8R, 
7'S, 8'S), and 2b (7R, 8R, 7'R, 8'R) and 2b' (7S, 8S, 7'S, 8'S), and the long distances between H-
7/H-8 and H-7'/H-8' (6.4-7.6 Å, Figure 16) restricted the use of ROESY spectrum for determining 







                             2 
Figure 16. Distances between protons of steric centers for compounds 2 (energy minimized by 
MM2 force field) 
 
The ECD spectra of 2a and 2b were calculated, and the experimental spectrum showed an 
inversed pattern of Cotton effects to 2a (Figure 17). Hence, compound 2 was assigned with the 
same configuration as 2a', and it was determined as a new sesquineolignan, (7"E)-(7R,8R,7'S,8'S)-
3,4,9,9',9"-pentahydroxy-7,4':7',4"-diepoxy-8,3':8',3"-bisoxysesquineolign-7"-ene, and was 
named americanol B. 
 
Figure 17. Experimental and calculated ECD spectra of compound 2 in MeOH, a and b 
represent the model configurations of each compound 
proton distance 
H-7 to H-7' 6.4 Å 
H-7 to H-8' 7.2 Å 
H-8 to H-7' 6.5 Å 







3.3.3. Moricitrin A 




2.0 (c 0.05, MeOH). Its molecular formula was determined as C36H34O12 based on the HRESIMS 
peak at m/z 657.1952 [M - H]- (calcd for 657.1967) and 1H and 13C NMR data (Table 1). It should 
be noted that the 1H and 13C NMR spectra only showed half of the total numbers of proton and 
carbon atoms present, suggesting that the structure consists of two identical moieties. The 13C 
NMR spectrum presented typical signals of four C6C3 units, with each including six aromatic 
carbons (δ 115-150) and three alkoxy carbons (δ 62-87), suggesting that compound 3 is a 
dineolignan. The 13C NMR signals at δ 87.0 (C-7, 7'), 55.3 (C-8, 8') and 72.7 (C-9, 9') and their 
corresponding 1H NMR signals at δ 4.66 (H-7, 7'), 3.04 (H-8, 8'), and 4.18 and 3.79 (H-9a, 9'a and 
9b, 9'b) suggested a symmetric furofuran-type moiety (124). In turn, the 
13C NMR signals at δ 77.6 
(C-7", 7'"), 79.9 (C-8", 8'") and 62.1 (C-9", 9'"), and the 1H NMR signals at δ 4.77 (H-7", 7'"), 3.97 
(H-8", 8'"), and 3.65 and 3.45 (H-9"a, 9'"a and 9"b, 9'"b) suggested a 1,4-benzodioxane-type unit to 
be present. Collectively, the structure of compound 3 was established as having a 3, 3'-
bisdemethylpinoresinol skeleton with symmetrical additions of two phenylpropanoid groups to C-
3 and C-4, and C-3' and C-4', respectively. The chemical shifts at δC 145.2 (C-3, 3') and 144.4 (C-
4, 4') were consistent with the signals of C-3' and C-4' in isoprincepin (53, 124), suggesting that 
the two dihydroxy-phenyl groups are located on the same side of the molecule as C-3 and C-3', 
respectively. The locations of the dihydroxy-phenyl groups were confirmed based on the detected 
HMBC correlations between H-7" and C-3, H-7'" and C-3', H-9"b (δ 3.45) and C-4, as well as H-
9'"b (δ 3.45) and C-4', after optimizing the proton-carbon coupling constant to 3 Hz (Figure 18). 







Figure 18. Key COSY (bold lines) and HMBC (blue arrows) correlations of compound 3 
 
The large coupling constants of J7",8" (8.0 Hz) and J 7'",8'" (8.0 Hz) suggested the trans 
substitutions of H-7" and H-8", and H-7'" and H-8'" in compound 3. The ROESY correlations were 
not detectable for establishing relative configurations due to the large distance from H-7" and H-
8" to H-7 and H-8, from H-7'" and H-8'" to H-7' and H-8' (6.2-7.1 Å, Figure 19).(124)  
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Figure 19. Distances between protons of steric centers for compounds 3 (energy minimized by 
MM2 force field) 
 
There are four theoretical configurations including 3a (7S, 8R, 7'S, 8'R, 7"S, 8"S, 7'"S, 8'"S), 
3a' (7R, 8S, 7'R, 8'S, 7"R, 8"R, 7'"R, 8'"R), 3b (7S, 8R, 7'S, 8'R, 7"R, 8"R, 7'"R, 8'"R) and 3b' (7R, 
8S, 7'R, 8'S, 7"S, 8"S, 7'"S, 8'"S). Among them, ECD spectra of 3a and 3b were simulated. The 
proton distance 
H-7 to H-7" 6.2 Å 
H-7 to H-8" 6.7 Å 
H-8 to H-7" 7.1 Å 







experimental results matched closely with the inverse Cotton effects of 3a (Figure 20), suggesting 
that compound 3 shares the same configuration with 3a'. Therefore, its structure was established 
as a new dineolignan, (7R,8S,7'R,8'S,7"R,8"R,7'"R,8'"R)-7,9':7',9:3,7":3',7'"-tetraepoxy-4,8":4',8'"-
bisoxy-8,8'-dineolignan-3",4",9",3'",4'",9'"-hexaol, named moricitrin A. 
 
Figure 20. Experimental and calculated ECD spectra of compound 3 in MeOH, a and b 
represent the model configurations of each compound 
 
3.3.4. Moricitrin B 




8.0 (c 0.05, MeOH). Its molecular formula was determined as C36H34O12, based on the HRESIMS 
peak at m/z 657.1954 [M - H]- (calcd for 657.1967) and 1H and 13C NMR data (Table 1). Compound 
4 was found also to be a symmetrical dineolignan that nominally showed half the actual numbers 
of protons and carbons in its NMR spectra. It was determined as a 3, 3'-bisdemethylpinoresinol 






signals contributed to this deduction. One set of signals at δC 87.0 (C-7, 7'), 55.4 (C-8, 8') and 72.7 
(C-9, 9'), and δH 4.67 (H-7, 7'), 3.06 (H-8, 8'), and 4.19 and 3.81 (H-9a, 9'a and 9b, 9'b) suggested a 
furofuran-type unit, and another set of signals at δC 77.6 (C-7", 7'"), 79.9 (C-8", 8'") and 62.1 (C-
9", 9'"), and δH 4.79 (H-7", 7'"), 3.98 (H-8", 8'"), and 3.65 and 3.45 (H-9"a, 9'"a and 9"b, 9'"b) 
suggested a 1,4-benzodioxane-type moiety. Also, the 13C NMR spectrum of 4 showed a pair of 
adjacent chemical shifts at δC 144.4 (C-3, 3') and 144.8 (C-4, 4'), rather than δC 144.4 and 145.2 as 
present in compound 3, suggesting a different connection of the two phenylpropanoid groups in 
compound 4. The adjacent signals were consistent with the signals of C-3' and C-4' in princepin 
(124), suggesting that the two dihydroxy-phenyl groups are located on the same side of the 
molecule as C-4 and C-4', while the two hydroxymethyl groups are near to C-3 and C-3'. These 
assignments were confirmed by HMBC (optimized coupling constant = 3 Hz) correlations between 
H-7" and C-4, H-7'" and C-4', H-9"b (δ 3.45) and C-3, and H-9'"b (δ 3.45) and C-3' (Figure 21). All 
the signals were assigned with the assistance of HSQC, COSY and HMBC NMR spectra. 
 
Figure 21. Key COSY (bold lines) and HMBC (blue arrows) correlations of compound 4 
 
Similar to compound 3, the trans relationships of H-7" and H-8", and H-7'" and H-8'" in 






J 7'",8'", and the ROESY correlations between H-7/H-8 and H-7"/H-8", and H-7'/H-8' and H-7'"/H-
8'" were not detectable due to the long distance between these two sets of steric centers (6.8-7.7 Å, 
Figure 22).  
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Figure 22. Distances between protons of steric centers for compounds 4 (energy minimized by 
MM2 force field) 
 
Among the four possible configurations, 4a (7S, 8R, 7'S, 8'R, 7"S, 8"S, 7'"S, 8'"S), 4a' (7R, 
8S, 7'R, 8'S, 7"R, 8"R, 7'"R, 8'"R), 4b (7S, 8R, 7'S, 8'R, 7"R, 8"R, 7'"R, 8'"R) and 4b' (7R, 8S, 7'R, 
8'S, 7"S, 8"S, 7'"S, 8'"S), the ECD spectra for 4a and 4b were calculated. The experimental data 
showed inverse Cotton effects with 4b (Figure 23). Thus, the structure of compound 4, named 




H-7 to H-7" 7.7 Å 
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Figure 23. Experimental and calculated ECD spectra of compound 4 in MeOH, a and b 









CHAPTER 4 Evaluation of Inhibitory Activities 
From the raw extract of noni fruits to the final mixture (F-3-2-2) containing compounds 1-
4, bioactive fractions were traced by inhibition assay against bacterial β-glucuronidase. Once 
purified 1-4 were obtained, their individual inhibitory activities were evaluated to confirm if they 
are the bioactive contributors to noni fruits. In the small intestine, there are also other important 
enzymes like α-amylase, α-glucosidase and pancreatic lipase that are responsible for the digestion 
of carbohydrates and triglycerides (127). Inhibition on these digestive enzymes may introduce 
additional adverse gastrointestinal (GI) effects. Therefore, compounds 1-4 were examined further 
for inhibitory activities against these enzymes to determine whether they are specific inhibitors 
against bacterial β-glucuronidase with minimal GI side effects. 
4.1. Inhibitory Assays on Enzymes 
4.1.1. Enzymes and Reagents  
All enzymes used in this study, including β-glucuronidase from Escherichia coli (500 kU), 
porcine pancreatic α-amylase (type VI-B), rat intestinal acetone powder, and pancreatic lipase 
(type VI-S), were purchased from Sigma-Aldrich (St. Louis, MO, USA). The substrates 4-methyl 
umbelliferyl-β-D-glucuronide hydrate, p-nitrophenyl-α- D-glucopyranoside (pNPG), and 4-methyl 
umbelliferyl oleate (4-MU oleate) were obtained from Sigma-Aldrich, potato starch powder was 
from Fisher Scientific (Fair Lawn, NJ, USA). Dinitrosalicylic acid reagent (DNS) from Sigma-
Aldrich (St. Louis, MO, USA) acted as an indicator for α-amylase assay. Acarbose (Alfa Aesar, 
Ward Hill, MA, USA), D-saccharic acid 1,4-lactone monohydrate (DSA, Sigma-Aldrich, St. Louis, 






absorbance and fluorescence of inhibitory assays were measured in EnSpire multimode plate 
reader (PerkinElmer, Waltham, MA, USA) 
4.1.2. Bacterial β-Glucuronidase Assay 
The inhibitory activities against bacterial β-glucuronidase were measured using black 96-
well microplates (42). Lyophilized samples were dissolved in 50% DMSO at various concentration 
levels. A portion (1.5 µL) of each was transferred into a well, followed by addition of 60 µL of β-
glucuronidase (6.25 U/mL). The mixture was incubated for 5 min at room temperature, then added 
with 40 µL of 4-methyl umbelliferyl-β- D-glucuronide hydrate (312.5 µM). After further 
incubation of 30 min at 37 °C, the fluorescence values were measured at an excitation wavelength 
of 355 nm and an emission wavelength of 460 nm. The results are expressed as percent inhibition 
compared with solvent control, and DSA was used as positive control. IC50 values were calculated 
based on inhibition percentages of series dilutions. 
4.1.3. α-Amylase Assay 
The α-amylase inhibitory activities were performed based on a previously established 
method with small modifications (128). The samples and α-amylase (4 U/mL) were mixed and 
incubated at room temperature for 5 min, then the substrate 0.5% potato starch solution was added 
and incubated for 3 min at 37 °C. After addition of DNS reagent and reaction of 10 min at 90 °C, 
25 µL of the cooled reaction mixture were loaded onto a 96-well plate and diluted with distilled 
water. The absorbance was measured at 540 nm, and the results are expressed as percent inhibition 







4.1.4. α-Glucosidase Assay  
Rat α-glucosidase was used to evaluate inhibitory activities (128). The enzyme was 
extracted from rat intestinal acetone powder with 0.1 M potassium phosphate buffer (pH 6.8). The 
samples and α-glucosidase (0.025 g/mL) were incubated at 37 °C for 3 min, then 4 mM pNPG 
were added and incubated for additional 30 min. The released p-nitrophenol from pNPG was 
measured at 405 nm, which was inversely related to the sample’s inhibition level. The results are 
expressed as percent inhibition compared with solvent control, with acarbose as positive control. 
4.1.5. Pancreatic Lipase Assay  
The enzyme inhibition was determined by measuring the released 4-methylumbelliferone 
from 4-MU oleate (128). In brief, the samples and lipase (50 U/mL) were mixed with the substrate 
4-MU oleate (0.1 mM), and incubated for 30 min at 37 °C. The fluorescence was measured at 
excitation of 355 nm and emission of 460 nm. The results are expressed as percent inhibition 
compared with solvent control, and orlistat (5 µg/mL) was used as positive control.  
4.1.6. Data Analysis  
Data from the bioactivity assays are reported as means ± SD, with the statistics analysis 
performed using SPSS for Windows (version 25, 2017, IBM). IC50 values were calculated by a 
probit procedure, and the statistical significance between groups was compared by one-way 
ANOVA and the Tukey’s test (p < 0.05 or 0.01). 
4.2. Specific Inhibition Against Bacterial β-Glucuronidase  
As shown in Table 7, the active compounds 1-4 exhibited potent inhibition against bacterial 






fold more potent than the positive control DSA, which gave an IC50 of 24.30 µM. It is also worth 
noting that the isolated natural dineolignans 3 and 4 were more active against β-glucuronidase than 
several synthesized novel inhibitors with IC50 values ranging from 1.7 to 4.8 µM (42). These results 
may lead to new applications for the bioactive components of M. citrifolia (noni). As a nutritional 
agent (52, 55), noni fruits could be developed into a safe and readily available dietary source to 
more effectively prevent irinotecan-induced diarrhea than those synthesized compounds by more 
potently inhibiting bacterial β-glucuronidase. 
Table 7. Inhibitory Activities against Bacterial β-Glucuronidase 
compound IC50
a (µM) ± SD 
1   6.91 ± 0.16e 
2   4.02 ± 0.06d 
3   0.62 ± 0.01c 
4   0.95 ± 0.01c 
DSAb 24.30 ± 0.80f 
a IC50 values in µM, and SD represents standard deviation (n = 3). 
b DSA (D-saccharic acid 1,4-
lactone monohydrate) was used as positive control. Different letters (c-f) represent significant 
differences with p < 0.01. 
  
Interestingly, the dineolignans (compounds 3 and 4) showed an order of magnitude more 
potent inhibition than the sesquineolignans (compounds 1 and 2), suggesting a strong structure-
activity relationship. Bacterial β-glucuronidase has a loop that is absent in human β-glucuronidase, 
and selective inhibitors exert their activity by binding to the overlapping loops at the tetramer 
interface of the enzyme (22, 33). Compared to the sesquineolignans (1 and 2), the dineolignans (3 
and 4) possess larger molecular sizes and more number of active hydroxy groups, which may 






compound 1 showed more potent β-glucuronidase inhibitory activity than compound 2, and the 
activity of compound 3 was also greater than that of compound 4, suggesting that their activities 
are also influenced by the substitution variations of hydroxypropenyl and dihydroxyphenyl groups. 
The results should provide valuable insights for searching for more effective inhibitors in the future. 
4.3. Inhibition on Digestive Enzymes   
As shown in Figure 24A, all the compounds showed no or weak effects on intestinal α-
amylase. At the concentrations of 0.1 and 0.5 mg/mL, none of them exhibited significant inhibition. 
When the concentration was increased to 1.0 mg/mL, compounds 2 (2.02 mM), 3 (1.52 mM) and 
4 (1.52 mM) showed weak inhibition on α-amylase (the highest inhibition was 21%) compared to 
the positive control acarbose, which resulted in 94% inhibition at 10 µg/mL (0.02 mM). Similar to 
α-amylase, α-glucosidase was only minimally inhibited by compounds 1-4 at concentrations up to 
1 mg/mL (Figure 24B). The highest inhibition of only 12% was from compound 1 at 1.0 mg/mL 
(2.02 mM), while acarbose showed 80% inhibitory activity at 0.02 mM. Figure 24C shows that 
compounds 1-4 exerted modest inhibition on lipase. At 0.1 mg/mL, all compounds exhibited 
inhibition of less than 56%, and their activities increased in the order from 1 to 4. Up to 1.0 mg/mL, 
they reached similar suppression values ranging from 85% to 93%, which were close to orlistat 
(96%). However, at this inhibition level, 1 (2.02 mM) and 2 (2.02 mM) were at a concentration 
level 200 times that of orlistat [0.01 mM (5 µg/mL)], while 3 (1.52 mM) and 4 (1.52 mM) were at 
a concentration 152 times that of orlistat (0.01 mM). Therefore, the inhibition of compounds 1-4 
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Figure 24. Inhibitory effects of compounds 1-4 against α-amylase (A), α-glucosidase (B) and 
pancreatic lipase (C). 
Acarbose (10 µg/mL) and orlistat (5 µg/mL) were used as positive controls. C1-4 represent 
compounds 1-4. The vertical bars represent the standard deviation (n = 3) for each data point, 






CHAPTER 5 Discussion 
5.1. Bioassay-guided Isolation 
Chemical constituents of natural resources are often more complex than expected in 
structural types and numbers. There are no fixed processes to do extraction and isolation for those 
constituents. However, the countless combinations of isolation processes are greatly decided by 
the purposes of specific projects. To characterize chemical constituents of rarely or newly studied 
natural materials, a systematic isolation is often performed to obtain as many compounds as 
possible. Isolation of specific type of constituents needs to be guided by their unique chemical 
properties. For instance, the basic property and selective reaction with Dragendroff’s reagent can 
be used to guide the isolation of alkaloids. Bioassay-guided isolation has been widely used for 
digging out active leads from chemical mixtures, such as paclitaxel from Taxus brevifolia and 
camptothecin from Camptotheca acuminata, they were successfully discovered following target 
bioactive assay (1). The aim of this project is to find out active compounds alleviating irinotecan-
induced delayed diarrhea, thus the procedure was started with the method establishment of 
appropriate in vitro biological assay (129). The diarrhea is caused by the intestinal SN-38 that is 
primarily produced by bacterial β-glucuronidase. Therefore, inhibitory assay against bacterial β-
glucuronidase was established to trace active compounds from extracts of noni fruits. 
During the isolation process, it is notable that activity of an extract or fraction is tested 
negative or weak doesn’t mean that it is not worth further investigation. The principle of “like 
dissolves like” concludes that polar/ionic solvents dissolve polar/ionic solutes and non-polar 
solvents dissolve non-polar solutes. Selection of extraction solvents greatly impact on what 






solvents or adjust ratio of solvent combination to obtain bioactive extractions in some cases. A 
famous example is the discovery of artemisinin (Qinghaosu). The success is attributed to the 
change of extract solvent from hot water to low-temperature ethyl ether by Tu Youyou who was 
awarded Nobel Prizes in 2015 (130, 131). 50% aqueous acetone was used to extract noni fruit 
powder in this project. It is a good solvent mixture to dissolve both nonpolar and polar substances, 
which ensured the chemical diversity and inclusion of active compounds for noni fruits extract. 
The weak activities of some fractions may be caused by relatively lower concentration of active 
components, which can be enhanced by enriching active compounds. As seen in this project, the 
raw extract of noni fruits showed only about 50% inhibition against bacterial β-glucuronidase at 
0.125 mg/mL. Along with continuous separation that get rid of inactive components, the inhibitory 
activities of refined fractions were increased up to 90%. Eventually, the strong inhibitors, 
compounds 1-4, were acquired with the assistance of bioassay. However, in some opposite cases, 
high activity of an extraction is a result of synergistic effects of low active components, which may 
turn out losing active targets after further separation (132, 133). This should be considered when 
using bioassay-guided isolation. 
5.2. Structure Elucidations 
Based on the characteristics of compounds 1-4, the commonly shared 1,4-benzodioxane 
moiety makes it challenging to elucidate their structures. Firstly, the two oxygen atoms impede the 
informative HMBC correlations across the1,4-dioxane ring, which was also observed in the 
reported compounds, such as isoamericanin A, americanol A, isoamericanol A, princepin, 
isoperincepin, isoamericanol B1, B2, C1, and C2 (124), haedoxancoside A (134), and 






the parameters of HMBC experiment can be optimized to achieve longer correlations (124). As 
shown in this investigation, the expected HMBC correlations across the 1,4-dioxane ring were 
presented after optimizing the proton-carbon coupling constant to 3 Hz. Secondly, the rigid plane 
of 1,4-benzodioxane separates the two steric centers of compounds 1-4 with theoretical distances 
in the range 6.2-8.0 Å (Figure 13, 16, 19 and 22). NOESY and ROESY correlations could be 
observed for protons separated typically by less than 5 Å (136, 137), thus, they are not applicable 
to establish the relative configurations for this type of molecules. 
ECD computation is often based on confirmed relative configurations, but also available 
for known possible relative configurations (138). Since the relative configurations were not 
decided, each of compounds 1-4 has eight configurations theoretically. Because the hydroxymethyl 
and dihydroxy-phenyl groups in each compound were assigned as trans substitutions, the numbers 
of possible configurations were reduced to four. Just based on these four possibilities, their 
absolute configurations were established through ECD calculation.  
5.3. In vitro Study 
In this study, purified compounds from noni fruits showed potent and specific inhibition 
against β-glucuronidase of Escherichia coli. However, there are still several essential steps needed 
to extrapolate this promising work to the clinical application alleviating irinotecan-induced 
delayed diarrhea. 
We conclude the inhibitory selectivity of our compounds 1-4 based on their none or weak 
inhibition against digestive enzymes. However, their inhibition on other lysosomal β-
glucuronidases of mammalian host may also need to be investigated. For instance, human β-






cancers, and potential target for the development of anti-inflammatory and anticancer drugs (139). 
Wallace et al. elucidated the crystal structure of the first bacterial β-glucuronidase from E. coli, 
and found that it has a 45% of sequence similarity with human β-glucuronidase (33). We don’t 
expect that our compounds 1-4 have side effects on glycosyl hydrolysis in host tissues and 
biofluids because of this similarity. It can be verified by measuring their inhibition against bovine 
liver β-glucuronidase, modified E. coli β-glucuronidase or other lysosomal β-glucuronidases (33). 
Wallace et al. also revealed that β-glucuronidase of E. coli possesses a unique “bacterial loop” of 
17 residues that is widely distributed in other human gut microbiota, while lacked in human β-
glucuronidase (33). Molecular docking study are used to investigate structure-activity relationship 
(SAR) between inhibitors and human β-glucuronidase (140-142). The inhibitory selectivity of 
compounds 1-4 can also be predicted through docking study that shows binding interactions of 
compounds with the key active sites of the bacterial loop. 
In another investigation by Wallace et al., β-glucuronidases from Streptococcus agalactiae 
and Clostridium perfringens of Firmicutes, Escherichia coli of Proteobacterium and Bacteroides 
fragilis of Bacteroidetes were compared together (11). These orthologous enzymes shared very 
similar structures but showed different catalytic properties and were variously inhibited by 
designed compounds. It suggests that our selective inhibitors against E. coli β-glucuronidase may 
also interact very differently with enzymes of other bacteria, which result in different net effect on 
the overall deconjugation of SN-38G. Therefore, we need to measure inhibition of our compounds 
on the enzyme of as more representative bacteria as possible, to evaluate their potential impacts 
on overall microbial β-glucuronidases. In addition, we need the most powerful data of animal and 
clinical experiments to convince our hypothesis that compounds 1-4 can alleviate irinotecan-






5.4. In vivo Study 
Balb/cJ mice are often used in cancer studies because of their tendency to develop different 
kinds of tumor (Figure 25). For instance, tumor-bearing Balb/cJ mice have been utilized for the 
discovery of irinotecan (CPT-11) (143). Unlike human β-glucuronidase, research on bacterial β-
glucuronidase inhibitors is a relatively new field that was firstly reported in 2010, and few of these 
inhibitors have reached animal experiment (139). In both investigations of Wallace et al. and 
Cheng et al., healthy Balb/cJ female mice were used to evaluate bacterial β-glucuronidase 
inhibitors’ effects in alleviating irinotecan-induced delayed diarrhea (33, 44). Therefore, healthy 
Balb/cJ model could also be used to assess our specific inhibitors. The experimental mice can be 
assigned into four groups and treated with 1) solvent of irinotecan intraperitoneally (i.p.) + solvent 
of inhibitor via oral gavage, 2) irinotecan + solvent of inhibitor, 3) solvent of irinotecan + inhibitor, 
4) irinotecan + inhibitor. The dose of inhibitor needs to be calculated carefully according to 
literature and preliminary experiment. 
 
Figure 25. Balb/cJ mouse 
 
Besides of inhibitors’ effects on delayed diarrhea, their influence on irinotecan’s anticancer 






al. showed that there was an obvious secondary peak of serum SN-38 level in patients infused 
intravenously with irinotecan (17). Kehrer et al. found that SN-38 could be transported across the 
membrane of colonic Caco-2 monolayers from apical to basolateral (144). These observations 
indicate that intestinal SN-38 may be reabsorbed into plasma to exert anticancer effect. In other 
words, inhibition of bacterial β-glucuronidase may reduce plasma SN-38 level and subsequently 
impair the therapeutic efficacy of irinotecan. As shown in the research on inhibitor pyrazolo[4,3-
c]quinoline derivative (TCH-3562) by Cheng et al. (44), monitoring the plasma pharmacokinetics 
of SN-38 is a practicable approach to learn the influence of our specific inhibitors on irinotecan’s 
efficacy. In addition, the inhibitors’ influence on the growth of gut bacteria can be determined by 
incubating our inhibitors with live bacteria, such as E. coli cells (44). It can also be examined by 
profiling entire gut microbial composition using16S rRNA sequencing (145). 
Up to date, there has no clinical trial been reported for inhibitors of E. coli β-glucuronidase 
in alleviating irinotecan-induced delayed diarrhea. Nevertheless, as mentioned above, some 
synthesized compounds have been shown strong inhibition on the enzyme. Animal studies have 
demonstrated their capacities in reducing delayed diarrhea and maintaining efficacy of irinotecan, 
while with limited impact on normal gut microbial community and the growth of epithelial cells. 
These researches have established a basic framework to develop inhibitors of bacterial β-
glucuronidase. Our compounds 1-4 possess potent and specific inhibition against the enzyme, and 
with minimized side effects on the intestinal digestion, which have been a solid foundation for 
further research and development. Moreover, our specific inhibitors are discovered from noni 
fruits, which is a widely distributed and dietary safe natural resource. Therefore, the noni fruits 
and their active compounds are promising to be developed as a dietary supplement or therapeutic 







HRESIMS (Figure A1-A4), and 1H, 13C, COSY, HSQC, HMBC and ROESY NMR spectra for 
(7S,8S,7'R,8'R)-isoamericanol B (1, Figure A5-A11), americanol B (2, Figure A12-A18), 







Figure A1. HRESIMS spectrum of (7S,8S,7'R,8'R)-isoamericanol B (1) 
 
 
Figure A2. HRESIMS spectrum of americanol B (2) 
H4_negative #23-38 RT: 0.62-1.03 AV: 16 NL: 3.33E6
T: FTMS - c ESI Full ms [150.00-1500.00]





































Figure A3. HRESIMS spectrum of moricitrin A (3) 
 
 
Figure A4. HRESIMS spectrum of moricitrin B (4) 
H6_negative #16-24 RT: 0.42-0.64 AV: 9 NL: 6.62E6
T: FTMS - c ESI Full ms [150.00-1500.00]
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Figure A5. HMBC (600 MHz, CD3OD, coupling constant = 3 Hz) spectrum of (7S,8S,7'R,8'R)-
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ABSTRACT:  
Irinotecan is a derived compound from the plant alkaloid camptothecin (CPT). It 
specifically inhibits eukaryotic DNA enzyme topoisomerase I. Irinotecan was approved by the 
FDA as the second-line therapy for metastatic colon or rectal cancer in 1996. However, one of its 
leading side effects is diarrhea. It has been reported that up to 88% of treated patients were 
suffering from diarrhea and 31% of cases with grade 3 or 4 diarrhea. Irinotecan is metabolized into 
SN-38G in the liver, then SN-38G is excreted to the intestinal tract and deconjugated back to SN-
38 by bacterial β-glucuronidase. The free SN-38 in the gut leads to the delayed diarrhea by 
damaging the intestinal mucosa. Therefore, selectively inhibiting bacterial β-glucuronidase has 
been an attractive strategy to alleviate irinotecan-induced delayed diarrhea. We preliminarily 
screened about 50 extracts and found that an extract of noni (Morinda citrifolia) fruits showed 






glucuronidase inhibitors were obtained following bioactive assay-guided isolation, including two 
sesquineolignans, (7S,8S,7'R,8'R)-isoamericanol B (1) and americanol B (2), and two dineolignans, 
moricitrin A (3) and B (4). Compounds 2-4 are new, and the absolute configuration of compound 
1 was determined for the first time. Their chemical structures were elucidated through HRESIMS 
and NMR spectra, and their absolute configurations were established via the comparison of the 
experimental and calculated electronic circular dichroism (ECD) spectra. These compounds 
showed potent inhibition against gut bacterial β-glucuronidase with IC50 values in the range 0.62-
6.91 µM. The inhibition presented specificity for β-glucuronidase as all the compounds showed 
no or weak effects on digestive enzymes such as α-amylase, α-glucosidase and lipase, suggesting 
that their gastrointestinal side effects could be minimized. These specific inhibitors as naturally 
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